CTAG1B (NY-ESO-1) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 15 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Immunotherapy Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for CTAG1B (NY-ESO-1) immunotherapy discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen CTAG1B (NY-ESO-1) Full-Length Recombinant Protein. High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. HEK293 Expressed (Native folding). Theoretical MW confirmed. View CTAG1B Products
Gene Delivery CTAG1B Lentivirus Particles / Promise-ORF Lentivirus. High-titer premade particles with puromycin selection for stable tumor cell line construction. >90% transduction efficiency. Full-length ORF, Endotoxin Controlled. View CTAG1B Products
Benchmark Ab Anti-CTAG1B (Clone E978 Sequence). Recombinant rabbit monoclonal positive control for IHC/Western validation. View CTAG1B Products
Validator CTAG1B siRNA Set. For knockdown specificity verification in target cells. View CTAG1B Products
Related Target: CTAG2 (LAGE-1) Co-expressed cancer/testis antigen; critical for cross-reactivity screening and dual-target strategies. View CTAG2 Products
Related Target: MAGEA4 Complementary cancer/testis antigen with distinct expression profile for combination therapy design. View MAGEA4 Products
Related Target: HLA-A Crucial for MHC-peptide presentation in TCR-T therapy. View HLA-A Products
Related Target: MAGEA3 Co-expressed cancer-testis antigen for combination targeting. View MAGEA3 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
TCR Cross-Reactivity Screening (CTAG family homology) High-purity CTAG1B, CTAG2, MAGEA4, and MAGEA3 ortholog proteins available; Sequence Verified for epitope mapping.
HLA-A*02:01 Peptide Presentation Assays Full-length CTAG1B protein for endogenous processing validation; Defined theoretical MW for loading calculations.
Stable Target Cell Line Generation Lentivirus particles with puromycin selection; Verified titers for consistent CTAG1B expression in HLA-A*02:01+ cell lines.
Assay Specificity Controls CTAG1B siRNA included for knockdown validation; Clinical benchmark antibodies included for positive controls.
Epitope Processing & Presentation High-purity recombinant proteins suitable for precise peptide mapping.

Live CTAG1B R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for CTAG1B (NY-ESO-1) therapeutics is intensifying, with major players shifting focus from traditional cancer vaccines to engineered TCR-T cell therapies and TCR-mimicking bispecific antibodies. Adaptimmune and Immatics are advancing Phase II programs in synovial sarcoma and multiple myeloma; Immunocore is pioneering TCR-mimic bispecifics; BioNTech and Immune Design have active cancer vaccine efforts. The next wave of R&D is targeting broader solid tumor indications (NSCLC, ovarian cancer), dual antigen strategies (e.g., combining CTAG1B with CTAG2 or MAGEA4) to mitigate immune escape, and combination with checkpoint inhibitors to overcome tumor microenvironment suppression.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
TCR-T Cell Therapy Adaptimmune, Immatics Synovial Sarcoma, Multiple Myeloma, Melanoma HLA-matched target cell lines (Lentivirus-transduced CTAG1B); TCR specificity validation.
Cancer Vaccines BioNTech, Immune Design Melanoma, Lung Cancer, Ovarian Cancer, NSCLC High-purity recombinant protein immunogens (>95% purity) with native folding; peptide-MHC binding assays.
TCR-like Bispecifics / TCR-Mimic Bispecifics Immunocore, TCR2 Therapeutics Solid Tumors Peptide-MHC complex binding assays; Affinity & specificity assays (need high-purity antigens); Cross-reactivity panels with related CTAG family.